

Highly Enantioselective and Regioselective Organocatalytic Direct Mannich Reaction of Methyl Alkyl Ketones with Cyclic Imines Benzo[e][1,2,3]oxathiazine 2,2-dioxides

You-Qing Wang,^{*a} Xiao-Yu Cui,^a Yuan-Yuan Ren^a and Yongna Zhang^{*a}

^a Provincial Key Laboratory of Natural Medicine and Immuno-Engineering, College of Chemistry and Chemical Engineering, Henan University, Kaifeng, Henan 475004, P. R. China.

Fax: (+86)-371-22864665; E-mail: wyouqing@hotmail.com; zhangyongna@henu.edu.cn

Supporting Information


Table of Contents.

1. General methods.....	S1
2. More results on the condition optimization of asymmetric Mannich reaction.....	S1-2
3. Procedure and data of asymmetric Mannich reaction.....	S2-6
4. X-ray structure for compound 2c	S6
Copy of NMR	S7-29
Copy of HPLC	S30-41

1. General methods.

General: ¹H NMR, and ¹³C NMR spectra were recorded on Bruker DRX-400 spectrometers. The chemical shifts for ¹H NMR were recorded in ppm (δ) relative to tetramethylsilane (TMS) with the solvent resonance employed as the internal standard (CDCl_3 , d 7.26 ppm). The chemical shifts for ¹³C NMR were recorded in ppm downfield using the central peak of deuteriochloroform (77.0 ppm) as the internal standard. Flash column chromatography was performed on silica gel (200-300 mesh). TLC analysis was performed using glass-backed plates coated with 0.2 mm silica. After elution, plate was visualized under at 254 nm UV illumination. All commercially available compounds were used as provided without further purification. The solvents were distilled from appropriate drying agents prior to use, unless otherwise noted. Cyclic imines **1** were prepared according to the procedures reported in the literature.^[1]

2. More results on the condition optimization of asymmetric Mannich reaction



Entry ^a	Acid	Solvent	Temp. (°C)	Time (h)	Yield (%)	ee (%)
1	TFA	THF	10	22	51	90
2	(+)-CSA	THF	10	72	35	96


¹ (a) S. R. Hanson, L. J. Whalen and C.-H. Wong, *Bioorg. Med. Chem.*, 2006, **14**, 8386; (b) Y. Wang, H. Dong, Y. Zhang and J. Li *Journal of Henan University(Natural Science)* 2013, **43**, 253; (c) Y.-Q. Wang, Y. Zhang, H. Dong, J. Zhang and J. Zhao, *Eur. J. Org. Chem.*, 2013, 3764.

3	TsOH	THF	10	72	50	95
4	AcOH	THF	10	96	0	-
5	TFA	Toluene	10	12	99	96
6	(+)-CSA	Toluene	10	84	71	94
7	(-)-CSA	Toluene	10	96	75	84
8	TFA	Toluene	0	24	99	91

The effects of acid were investigated in THF (entries 1-4). In spite of the best *ee*, the reaction was slower with (+)-CSA than TFA (entries 1 vs 2). However, in optimized solvent (Toluene) TFA afforded the better reactivities and enantioselectivities than CSA (entries 5-7). While temperature was decreased to 0°C, a slightly lower ee values was obtained (entry 8).

3. Procedure and data of asymmetric Mannich reaction


Typical procedure: To the mixture of quinine-NH₂ **C-4** (0.015 mmol, 10 mol%) and cyclic imine **1** (0.15 mmol) in toluene (1.45 mL) was added the solution of TFA (0.03 mmol, 20 mol%) in toluene (0.05 mL). After the reaction mixture was cooled to 10°C, acetone (0.75 mmol) was added. This reaction mixture was stirred in showed reaction time. Direct purification reaction mixture by column chromatography on a silica gel (petroleum ether/DCM) gave the desired Mannich products. The enantiomeric excess was determined by HPLC. Racemic Mannich products were obtained with the combination of 10 mol% benzyl amine and 20 mol% TFA.



2a: Known compound²; $R_f = 0.18$ (CH_2Cl_2); 96% *ee*, $[\alpha]^{32}_{\text{D}} = -21.3$ (*c* 0.97, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 7.31 (t, $J = 7.6$ Hz, 1H), 7.17 (t, $J = 7.5$ Hz, 1H), 7.11-7.10 (m, 1H), 7.02 (d, $J = 8.2$ Hz, 1H), 5.82 (s, 1H), 5.17 (dd, $J = 7.2, 3.8$ Hz, 1H), 3.62 (dd, $J = 18.1, 7.5$ Hz, 1H), 2.97 (dd, $J = 18.1, 3.8$ Hz, 1H), 2.24 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 206.7, 151.1, 129.6, 125.8, 125.4, 121.3, 119.1, 53.3, 46.4, 31.0; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): $t_1 = 10.1$ min (major, S), $t_2 = 15.0$ min.



2b: White solid; mp 114.4-115.3°C; $R_f = 0.30$ (CH_2Cl_2); 96% *ee*, $[\alpha]^{32}_{\text{D}} = -18.4$ (*c* 1.03, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 7.03-6.96 (m, 2H), 6.84-6.81 (m, 1H), 5.89 (s, 1H), 5.14 (dd, $J = 6.7, 3.9$ Hz, 1H), 3.57 (dd, $J = 18.3, 7.4$ Hz, 1H), 2.98 (dd, $J = 18.3, 4.1$ Hz, 1H), 2.24 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 206.6, 159.3 (d, $^1J_{\text{F-C}} = 244.3$ Hz), 147.0 (d, $^4J_{\text{F-C}} = 2.7$ Hz), 123.1 (d, $^3J_{\text{F-C}} = 7.1$ Hz), 120.6 (d, $^3J_{\text{F-C}} = 8.3$ Hz), 116.6 (d, $^2J_{\text{F-C}} = 23.5$ Hz), 112.7 (d, $^2J_{\text{F-C}} = 24.8$ Hz), 53.0, 46.4, 30.8; HRMS (ESI): m/z calculated for $\text{C}_{10}\text{H}_{10}\text{FNNaO}_4\text{S} [\text{M}+\text{Na}]^+$ 282.0207, found: 282.0210; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): $t_1 = 8.5$ min (major, S), $t_2 = 10.7$ min.



2c: White solid; mp 123.2-124.1°C; $R_f = 0.34$ (CH_2Cl_2); 97% *ee*, $[\alpha]^{30}_{\text{D}} = -52.3$ (*c* 1.17, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 7.28 (ddd, $J = 8.8, 2.4, 0.5$ Hz, 1H), 7.10 – 7.09 (m, 1H), 6.98 (d, $J = 8.8$ Hz, 1H), 5.78 (d, $J = 5.2$ Hz, 1H), 5.14 (d, $J = 3.6$ Hz, 1H), 3.61 (dd, $J = 18.4, 7.2$ Hz, 1H), 2.99 (dd, $J = 18.4, 4.0$ Hz, 1H), 2.26 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 206.3, 149.7, 130.7, 129.7, 125.7, 122.9, 120.5, 53.1, 46.1, 30.9; HRMS (ESI): m/z calculated for $\text{C}_{10}\text{H}_{10}\text{ClNaO}_4\text{S} [\text{M}+\text{Na}]^+$ 297.9911, found: 297.9914; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): $t_1 = 7.2$ min

² H.-X. Zhang, J. Nie, H. Cai and J.-A. Ma *Org. Lett.*, 2014, **16**, 2542.

(major, *S*), $t_2 = 8.5$ min.

2d: White solid; mp 125.3-126.6°C; $R_f = 0.34$ (CH_2Cl_2); 91% *ee*, $[\alpha]^{30}_{\text{D}} = -42.3$ (*c* 0.93, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 7.42 (d, $J = 8.2$ Hz, 1H), 7.25 (s, 1H), 6.92 (d, $J = 8.6$ Hz, 1H), 5.82 (s, 1H), 5.15 (s, 1H), 3.61 (dd, $J = 18.3, 7.0$ Hz, 1H), 2.98 (dd, $J = 167.6, 1.2$ Hz, 1H), 2.26 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 206.4, 150.1, 132.6, 128.7, 123.3, 120.8, 118.1, 52.9, 46.3, 30.9; HRMS (ESI): m/z calculated for $\text{C}_{10}\text{H}_{10}\text{BrNNaO}_4\text{S} [\text{M}+\text{Na}]^+$ 341.9406, found: 341.9408; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): $t_1 = 7.4$ min (major, *S*), $t_2 = 8.7$ min.

2e: White solid; mp 111.9-112.6°C; $R_f = 0.29$ (CH_2Cl_2); 95% *ee*, $[\alpha]^{30}_{\text{D}} = -46.8$ (*c* 1.06, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 7.08 (d, $J = 8.4$ Hz, 1H), 6.89-6.88 (m, 2H), 5.78 (s, 1H), 5.12 (s, 1H), 3.59 (dd, $J = 18.1, 7.9$ Hz, 1H), 2.94 (dd, $J = 18.1, 3.8$ Hz, 1H), 2.30 (s, 3H), 2.23 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 206.7, 149.00, 135.2, 130.2, 126.1, 120.9, 118.8, 53.3, 46.6, 31.0, 20.8; HRMS (ESI): m/z calculated for $\text{C}_{11}\text{H}_{13}\text{NNaO}_4\text{S} [\text{M}+\text{Na}]^+$ 278.0458, found: 278.0464; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): $t_1 = 10.1$ min (major, *S*), $t_2 = 12.1$ min.

2f: White solid; mp 89.3-89.7°C; $R_f = 0.27$ (CH_2Cl_2); 95% *ee*, $[\alpha]^{30}_{\text{D}} = -35.1$ (*c* 1.30, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 6.94 (d, $J = 9.0$ Hz, 1H), 6.82 (dd, $J = 9.0, 2.8$ Hz, 1H), 6.60 (d, $J = 2.8$ Hz, 1H), 5.76 (d, $J = 7.5$ Hz, 1H), 5.12 (d, $J = 3.8$ Hz, 1H), 3.76 (s, 3H), 3.58 (dd, $J = 18.1, 7.7$ Hz, 1H), 2.95 (dd, $J = 18.1, 3.9$ Hz, 1H), 2.23 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 206.9, 160.3, 151.8, 126.4, 113.0, 112.4, 103.8, 55.6, 53.0, 46.3, 31.1; HRMS (ESI): m/z calculated for $\text{C}_{11}\text{H}_{13}\text{NNaO}_5\text{S} [\text{M}+\text{Na}]^+$ 294.0407, found: 294.0409; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): $t_1 = 10.3$ min (major, *S*), $t_2 = 12.3$ min.

2g: Colorless oil; $R_f = 0.23$ (CH_2Cl_2); 96% *ee*, $[\alpha]^{30}_{\text{D}} = -27.3$ (*c* 1.17, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 6.94 (d, $J = 8.6$ Hz, 1H), 6.66 (dd, $J = 8.6, 2.1$ Hz, 1H), 6.45 (s, 1H), 5.06 (dd, $J = 7.7, 3.8$ Hz, 1H), 4.83 (s, 1H), 3.75 (s, 3H), 3.47 (dd, $J = 17.7, 8.0$ Hz, 1H), 2.88 (dd, $J = 17.8, 3.7$ Hz, 1H), 2.19 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 206.9, 160.3, 151.8, 126.4, 113.0, 112.4, 103.8, 55.6, 53.0, 46.3, 31.1; HRMS (ESI): m/z calculated for $\text{C}_{11}\text{H}_{13}\text{NNaO}_5\text{S} [\text{M}+\text{Na}]^+$ 294.0407, found: 294.0410; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): $t_1 = 15.2$ min (major, *S*), $t_2 = 21.7$ min.

2h: White solid; mp 116.2-117.0°C; $R_f = 0.21$ (CH_2Cl_2); 95% *ee*, $[\alpha]^{31}_{\text{D}} = -24.3$ (*c* 1.44, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 7.08 (t, $J = 8.1$ Hz, 1H), 6.87 (d, $J = 7.9$ Hz, 1H), 6.66 (d, $J = 7.9$ Hz, 1H), 5.84 (s, 1H), 5.16 (s, 1H), 3.84 (s, 3H), 3.59 (dd, $J = 18.1, 7.6$ Hz, 1H), 2.94 (dd, $J = 18.1, 3.9$ Hz, 1H), 2.22 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 206.7, 156.7, 144.8, 122.2, 119.9, 114.5, 111.1, 55.7, 53.4, 46.5, 31.0; HRMS (ESI): m/z calculated for $\text{C}_{11}\text{H}_{13}\text{NNaO}_5\text{S} [\text{M}+\text{Na}]^+$ 294.0407, found: 294.0411; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): $t_1 = 15.0$ min (major, *S*), $t_2 = 26.6$ min.

2i: White solid; mp 133.9-135.1°C; $R_f = 0.28$ (CH_2Cl_2); 97% *ee*, $[\alpha]^{31}_{\text{D}} = -12.6$ (*c* 1.00, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 7.69-7.67 (m, 1H), 7.19 (s, 1H), 5.98 (s, 1H), 5.15 (s, 1H), 3.64-3.56 (m, 1H), 2.99 (d, $J = 18.4$ Hz, 1H), 2.26-2.25 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 206.2, 147.3, 135.8, 127.7, 124.8, 117.9,

113.9, 53.1, 46.2, 30.9; HRMS (ESI): m/z calculated for $C_{10}H_9Br_2NNaO_4S$ [M+Na]⁺ 419.8511, found: 419.8514; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): t_1 = 6.3 min (major, *S*), t_2 = 7.9 min.

2j: White solid; mp 121.7-122.2°C; R_f = 0.26 (CH_2Cl_2); 96% ee, $[\alpha]^{32}_D$ = -6.1 (*c* 1.12, $CHCl_3$); ¹H NMR (400 MHz, $CDCl_3$): δ 7.54 (d, *J* = 2.1 Hz, 1H), 7.05 (d, *J* = 1.8 Hz, 1H), 5.95 (s, 1H), 5.15 (s, 1H), 3.60 (dd, *J* = 18.4, 7.2 Hz, 1H), 3.00 (dd, *J* = 18.4, 4.0 Hz, 1H), 2.26 (s, 3H); ¹³C NMR (100 MHz, $CDCl_3$): δ 206.2, 146.8, 133.1, 130.8, 124.9, 124.4, 113.5, 53.1, 46.3, 30.8; HRMS (ESI): m/z calculated for $C_{10}H_9BrClNNaO_4S$ [M+Na]⁺ 375.9016, found: 375.9015; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): t_1 = 6.1 min (major, *S*), t_2 = 7.8 min.

2k: White solid; mp 143.3-144.5°C; R_f = 0.29 (CH_2Cl_2); 93% ee, $[\alpha]^{31}_D$ = -37.3 (*c* 1.00, $CHCl_3$); ¹H NMR (400 MHz, $CDCl_3$): δ 7.33 (d, *J* = 2.2 Hz, 1H), 6.94 (d, *J* = 2.0 Hz, 1H), 5.74 (s, 1H), 5.15 (dd, *J* = 8.4, 3.8 Hz, 1H), 3.61 (dd, *J* = 17.9, 8.5 Hz, 1H), 2.92 (dd, *J* = 17.9, 3.9 Hz, 1H), 2.24 (s, 3H), 1.40 (s, 9H), 1.28 (s, 9H); ¹³C NMR (100 MHz, $CDCl_3$): δ 206.8, 148.0, 147.6, 139.4, 124.3, 121.8, 120.7, 53.6, 47.4, 35.1, 34.6, 31.3, 30.9, 30.0; HRMS (ESI): m/z calculated for $C_{18}H_{27}NNaO_4S$ [M+Na]⁺ 376.1553, found: 376.1557; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): t_1 = 5.8 min (major, *S*), t_2 = 6.4 min.


4a: Known compound²; R_f = 0.34 (CH_2Cl_2); 96% ee, $[\alpha]^{31}_D$ = -26.7 (*c* 0.97, $CHCl_3$); ¹H NMR (400 MHz, $CDCl_3$): δ 7.33-7.29 (m, 1H), 7.17 (td, *J* = 7.6, 1.0 Hz, 1H), 7.11-7.09 (m, 1H), 7.03 (dd, *J* = 8.2, 0.8 Hz, 1H), 5.78 (d, *J* = 4.3 Hz, 1H), 5.19 (d, *J* = 3.4 Hz, 1H), 3.61 (dd, *J* = 17.9, 7.5 Hz, 1H), 2.93 (dd, *J* = 17.9, 3.9 Hz, 1H), 2.58-2.46 (m, 2H), 1.06 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (100 MHz, $CDCl_3$): δ 209.5, 151.2, 129.6, 125.7, 125.4, 121.4, 119.2, 53.6, 45.0, 37.2, 7.4; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): t_1 = 9.5 min (major, *S*), t_2 = 15.9 min.

4b: Known compound²; R_f = 0.18 (CH_2Cl_2); 95% ee, $[\alpha]^{31}_D$ = -21.3 (*c* 0.97, $CHCl_3$); ¹H NMR (400 MHz, $CDCl_3$): δ 7.32-7.27 (m, 1H), 7.16 (td, *J* = 7.5, 0.8 Hz, 1H), 7.10 (d, *J* = 7.5 Hz, 1H), 7.00 (d, *J* = 8.2 Hz, 1H), 5.93 (d, *J* = 8.0 Hz, 1H), 5.18 (td, *J* = 7.8, 3.9 Hz, 1H), 3.58 (dd, *J* = 17.9, 7.7 Hz, 1H), 2.91 (dd, *J* = 17.9, 3.9 Hz, 1H), 2.48-2.43 (m, 2H), 1.59 (dd, *J* = 14.7, 7.4 Hz, 2H), 0.89 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, $CDCl_3$): δ 209.3, 151.1, 129.5, 125.8, 125.4, 121.4, 119.0, 53.4, 45.7, 45.5, 16.8, 13.5; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): t_1 = 8.3 min (major, *S*), t_2 = 13.3 min.


4c: White solid; mp 43.1-44.3°C; R_f = 0.56 (CH_2Cl_2); 97% ee, $[\alpha]^{31}_D$ = -31.4 (*c* 0.92, $CHCl_3$); ¹H NMR (400 MHz, $CDCl_3$): δ 7.32-7.29 (m, 1H), 7.16 (t, *J* = 7.1 Hz, 1H), 7.10 (d, *J* = 7.6 Hz, 1H), 7.01 (d, *J* = 8.2 Hz, 1H), 5.90 (s, 1H), 5.18 (s, 1H), 3.59 (dd, *J* = 17.9, 7.6 Hz, 1H), 2.91 (dd, *J* = 17.9, 3.9 Hz, 1H), 2.54-2.41 (m, 2H), 1.58-1.50 (m, 2H), 1.33-1.24 (m, 2H), 0.88 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (100 MHz, $CDCl_3$): δ 209.4, 151.1, 129.5, 125.8, 125.4, 121.4, 119.0, 53.4, 45.5, 43.6, 25.4, 22.1, 13.7; HRMS (ESI): m/z calculated for $C_{13}H_{17}NNaO_4S$ [M+Na]⁺ 306.0771, found: 306.0773; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): t_1 = 7.3 min (major, *S*), t_2 = 12.4 min.

4d: Yellow solid; mp 36.3-37.5°C; R_f = 0.47 (CH_2Cl_2); 96% ee, $[\alpha]^{32}_D$ = -31.4 (*c*


0.97, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 7.29 (t, $J = 7.7$ Hz, 1H), 7.18-7.14 (m, 1H), 7.10 (d, $J = 7.5$ Hz, 1H), 7.00 (d, $J = 8.2$ Hz, 1H), 5.96 (s, 1H), 5.18 (td, $J = 7.8, 4.0$ Hz, 1H), 3.58 (dd, $J = 18.0, 7.6$ Hz, 1H), 2.88 (dd, $J = 18.0, 3.9$ Hz, 1H), 2.35 (d, $J = 7.0$ Hz, 2H), 2.17-2.07 (m, 1H), 0.89 (dd, $J = 6.6, 2.5$ Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3): δ 209.1, 151.1, 129.5, 1265.9, 125.3, 121.5, 119.0, 53.3, 52.7, 46.0, 24.4, 22.4, 22.3; HRMS (ESI): m/z calculated for $\text{C}_{13}\text{H}_{17}\text{NNaO}_4\text{S} [\text{M}+\text{Na}]^+$ 306.0771, found: 306.0774; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): $t_1 = 6.4$ min (major, S), $t_2 = 8.8$ min.




4e: White solid; mp 76.5-77.8°C; $R_f = 0.32$ (PE/EtOAc, 5:1); 87% ee, $[\alpha]^{32}_D = -38.1$ (*c* 1.25, CHCl_3); ^1H NMR (400 MHz, CDCl_3): 87.33-7.28 (m, 1H), 7.16 (td, $J = 7.5, 1.0$ Hz, 1H), 7.10-7.08 (m, 1H), 7.02 (dd, $J = 8.3$ Hz, 1.0 Hz, 1H), 5.87 (d, $J = 8.0$ Hz, 1H), 5.20-5.15 (m, 1H), 3.59 (dd, $J = 18.0, 7.3$ Hz, 1H), 2.89 (dd, $J = 18.0, 3.9$ Hz, 1H), 2.34 (d, $J = 6.9$ Hz, 2H), 1.87-1.76 (m, 1H), 1.68-1.60 (m, 4H), 1.30-1.06 (m, 4H), 0.96-0.82 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 209.1, 151.2, 129.6, 125.8, 125.3, 121.4, 119.2, 53.5, 51.6, 45.8, 33.8, 33.2, 33.1, 26.1, 26.02, 25.98; HRMS (ESI): m/z calculated for $\text{C}_{16}\text{H}_{21}\text{NNaO}_4\text{S} [\text{M}+\text{Na}]^+$ 346.1089, found: 346.1088; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): $t_1 = 7.2$ min (major, S), $t_2 = 9.3$ min.




4f: White solid; mp 121.7-122.2°C; $R_f = 0.29$ (PE/EtOAc, 3:1); 92% ee, $[\alpha]^{32}_D = -13.8$ (*c* 1.73, CHCl_3); ^1H NMR (400 MHz, CDCl_3): 87.32-7.28 (m, 1H), 7.15-7.11 (m, 2H), 7.09-7.07 (m, 1H), 7.06-7.00 (m, 3H), 6.90 (d, $J = 8.0$ Hz, 7.7H), 5.66 (d, $J = 8.1$ Hz, 1H), 5.14 (td, $J = 7.8, 3.9$ Hz, 1H), 3.74 (s, 2H), 3.66 (dd, $J = 18.0, 7.5$ Hz, 1H), 2.92 (dd, $J = 18.0, 3.9$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 206.1, 162.2 (d, $^1J_{\text{F-C}} = 245.0$ Hz), 151.1, 131.1 (d, $^3J_{\text{F-C}} = 8.0$ Hz), 129.7, 128.38 (d, $^4J_{\text{F-C}} = 3.3$ Hz), 125.6, 125.4, 121.0, 119.1, 115.9 (d, $^2J_{\text{F-C}} = 21.4$ Hz), 53.5, 50.0, 44.6; HRMS (ESI): m/z calculated for $\text{C}_{16}\text{H}_{14}\text{FNNaO}_4\text{S} [\text{M}+\text{Na}]^+$ 358.0525, found: 358.0510; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): $t_1 = 8.8$ min (major, S), $t_2 = 12.0$ min.



4g: White solid; mp 121.7-122.2°C; $R_f = 0.29$ (PE/EtOAc, 3:1); 94% ee, $[\alpha]^{32}_D = -6.8$ (*c* 1.66, CHCl_3); ^1H NMR (400 MHz, CDCl_3): 87.31-7.28 (m, 3H), 7.12-7.08 (m, 3H), 7.01-6.99 (m, 1H), 6.91 (d, $J = 7.7$ Hz, 1H), 5.69 (s, 1H), 5.14 (d, $J = 3.5$ Hz, 1H), 3.73 (s, 2H), 3.66 (dd, $J = 18.0, 7.7$ Hz, 1H), 2.92 (dd, $J = 18.0, 3.9$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 205.9, 151.1, 133.5, 131.1, 130.8, 129.7, 129.1, 125.7, 125.4, 121.0, 119.1, 53.5, 50.1, 44.9; HRMS (ESI): m/z calculated for $\text{C}_{16}\text{H}_{14}\text{ClNNaO}_4\text{S} [\text{M}+\text{Na}]^+$ 374.0230, found: 374.0198; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): $t_1 = 9.3$ min (major, S), $t_2 = 12.3$ min.




4h: White solid; mp 121.7-122.2°C; Yellow solid; mp 102.7-103.8°C; $R_f = 0.43$ (CH_2Cl_2); 94% ee, $[\alpha]^{31}_D = 6.1$ (*c* 1.73, CHCl_3); ^1H NMR (400 MHz, CDCl_3): 87.30-7.25 (m, 1H), 7.09-7.04 (m, 3H), 6.99 (d, $J = 8.3$ Hz, 1H), 6.88-6.84 (m, 3H), 5.79 (s, 1H), 5.10 (d, $J = 3.4$ Hz, 1H), 3.80 (s, 3H), 3.68 (s, 2H), 3.63 (dd, $J = 18.1, 7.2$ Hz, 1H), 2.90 (dd, $J = 18.1, 3.9$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3): δ 207.0, 158.9, 151.1, 130.5, 129.5, 125.7, 125.3, 124.7, 121.1, 118.9, 55.2, 53.4, 50.0, 44.1; HRMS (ESI): m/z calculated for $\text{C}_{17}\text{H}_{17}\text{NNaO}_5\text{S} [\text{M}+\text{Na}]^+$ 370.0720, found: 370.0719; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): $t_1 = 16.3$ min (major, S), $t_2 = 37.5$ min.




4i: White solid; mp 36.3-37.5°C; $R_f = 0.57$ (CH_2Cl_2); 96% ee, $[\alpha]^{31}_D = -23.4$ (*c* 0.98, CHCl_3); ^1H NMR (400 MHz, CDCl_3): 87.31-7.25 (m, 3H), 7.19 (t, $J = 7.3$


Hz, 1H), 7.15-7.11 (m, 3H), 7.00 (d, J = 8.4 Hz, 1H), 5.78 (s, 1H), 5.16 (d, J = 3.6 Hz, 1H), 3.56 (dd, J = 18.0, 7.7 Hz, 1H), 2.90-2.79 (5, 2H); ^{13}C NMR (100 MHz, CDCl_3): δ 208.1, 151.1, 140.2, 129.6, 128.6, 128.2, 126.3, 125.8, 125.4, 121.2, 119.1, 53.3, 45.9, 45.1, 29.3; HRMS (ESI): m/z calculated for $\text{C}_{17}\text{H}_{17}\text{NNaO}_4\text{S} [\text{M}+\text{Na}]^+$ 354.0771, found: 354.0771; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): t_1 = 9.9 min (major, S), t_2 = 15.9 min.



4j: Known compound²; R_f = 0.49 (CH_2Cl_2); 96% ee, $[\alpha]^{20}_{\text{D}} = -51.2$ (c 1.44 in CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 7.30 (t, J = 7.8 Hz, 1H), 7.17 (t, J = 7.5 Hz, 1H), 7.09 (m, 1H), 7.02 (dd, J = 8.2, 1.9 Hz, 1H), 5.84 (d, J = 10.9 Hz, 1H), 5.20 (s, 1H), 3.69 (dd, J = 18.1, 7.6 Hz, 1H), 2.93 (dd, J = 18.1, 3.8 Hz, 1H), 2.64 (m, J = 6.9 Hz, 1H), 1.11 (t, J = 6.8 Hz, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 212.8, 151.1, 129.6, 125.8, 125.4, 121.4, 119.1, 53.5, 43.5, 41.6, 17.8, 17.7; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min 220 nm): t_1 = 6.6 min (major), t_2 = 10.7 min (minor).




4k: Known compound²; R_f = 0.51 (CH_2Cl_2); 97% ee, $[\alpha]^{32}_{\text{D}} = -19.4$ (c 0.97, CHCl_3); ^1H NMR (400 MHz, CDCl_3): δ 7.31-7.27 (m, 1H), 7.16 (td, J = 7.5, 1.0 Hz, 1H), 7.08 (m, 1H), 7.00 (d, J = 8.3 Hz, 1H), 5.92 (s, 1H), 5.19 (d, J = 3.7 Hz, 1H), 3.67 (dd, J = 18.2, 7.6 Hz, 1H), 2.91 (dd, J = 18.2, 3.9 Hz, 1H), 2.38-2.34 (m, 1H), 1.87-1.81 (m, 2H), 1.79-1.76 (m, 2H), 1.68-1.65 (m, 1H), 1.39-1.29 (m, 2H), 1.25-1.15 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3): δ 212.1, 151.2, 129.5, 125.8, 125.3, 121.5, 119.1, 53.4, 51.3, 43.6, 28.1, 28.0, 25.6, 25.4; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min, 220 nm): t_1 = 6.9 min (major, S), t_2 = 12.5 min.




4l: Known compound²; R_f = 0.41 (CH_2Cl_2); 95% ee, $[\alpha]^{30}_{\text{D}} = -43.92$ (c 1.11 in CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 7.32 – 7.28 (m, 1H), 7.19 – 7.12 (m, 2H), 7.01 (d, J = 8.2 Hz, 1H), 5.96 (s, 1H), 5.17 (dd, J = 7.0, 3.8 Hz, 1H), 3.72 (dd, J = 18.0, 7.2 Hz, 1H), 3.11 (dd, J = 18.0, 3.9 Hz, 1H), 2.02 – 1.96 (m, 1H), 1.13 – 1.07 (m, 1H), 1.04 – 0.93 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 209.0, 151.2, 129.5, 125.8, 125.3, 121.5, 119.0, 53.4, 45.7, 21.7, 11.7.5, 11.71; HPLC (Chiralcel IC column, hexane/iPrOH = 70/30, 0.8 mL/min 220 nm): t_1 = 9.7 min (major), t_2 = 13.7 min (minor).



4. X-ray structure for compound 2c



The needle-like crystals of the compound **2c** were grown from its solution in dichloromethane and hexane, and one of them is suitable for X-ray diffraction analysis. The correctness of the X-ray data and the structure had been checked by using the CheckCIF utility on the submission Web site: <http://checkcif.iucr.org>.





Copy of NMR

















2e






2e






























































HPLC for racemic and pure enantioenriched sample **2a**






HPLC for racemic and pure enantioenriched sample **2b**





HPLC for racemic and pure enantioenriched sample **2c**





HPLC for racemic and pure enantioenriched sample **2d**




HPLC for racemic and pure enantioenriched sample **2e**






HPLC for racemic and pure enantioenriched sample **2f**




HPLC for racemic and pure enantioenriched sample **2g**






HPLC for racemic and pure enantioenriched sample **2h**




HPLC for racemic and pure enantioenriched sample **2i**






HPLC for racemic and pure enantioenriched sample **2j**




HPLC for racemic and pure enantioenriched sample **2k**






HPLC for racemic and pure enantioenriched sample **4a**




HPLC for racemic and pure enantioenriched sample **4b**






HPLC for racemic and pure enantioenriched sample **4c**




HPLC for racemic and pure enantioenriched sample **4d**






HPLC for racemic and pure enantioenriched sample **4e**




HPLC for racemic and pure enantioenriched sample **4f**






HPLC for racemic and pure enantioenriched sample **4g**




HPLC for racemic and pure enantioenriched sample **4h**






HPLC for racemic and pure enantioenriched sample **4i**




HPLC for racemic and pure enantioenriched sample **4j**



HPLC for racemic and pure enantioenriched sample **4k**




HPLC for racemic and pure enantioenriched sample 4l



信号 2: DAD1 C, Sig=220,8 Ref=360,100

峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]	峰面积 %
1	9.749	MM	0.2562	6590.99561	428.69244	50.4559
2	13.656	MM	0.3562	6471.88281	302.83783	49.5441

总量 : 1.30629e4 731.53027



信号 2: DAD1 C, Sig=220,8 Ref=360,100

峰 #	保留时间 [min]	类型	峰宽 [min]	峰面积 [mAU*s]	峰高 [mAU]	峰面积 %
1	9.710	MM	0.2752	2.07564e4	1257.24915	97.4208
2	13.656	MM	0.3172	549.53210	28.87473	2.5792

总量 : 2.13060e4 1286.12388